These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 38944486)
1. Pediatric Immune Thrombocytopenia. Gotesman M; Shear M; Raheel S; Procassini M; Panosyan EH Adv Pediatr; 2024 Aug; 71(1):229-240. PubMed ID: 38944486 [TBL] [Abstract][Full Text] [Related]
2. Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama. Watts RG Clin Pediatr (Phila); 2004 Oct; 43(8):691-702. PubMed ID: 15494875 [TBL] [Abstract][Full Text] [Related]
3. [Idiopathic thrombocytopenic purpura in children]. Gebauer E; Vijatov G Med Pregl; 1998; 51(3-4):127-34. PubMed ID: 9611955 [TBL] [Abstract][Full Text] [Related]
4. A proposal for new definition (s) and management approach to paediatric refractory ITP: Reflections from the Intercontinental ITP Study Group. Neunert C; Heitink-Polle KMJ; Lambert MP Br J Haematol; 2023 Oct; 203(1):17-22. PubMed ID: 37641973 [TBL] [Abstract][Full Text] [Related]
5. Treatment of immune thrombocytopenic purpura in children : current concepts. Shad AT; Gonzalez CE; Sandler SG Paediatr Drugs; 2005; 7(5):325-36. PubMed ID: 16220997 [TBL] [Abstract][Full Text] [Related]
6. A clinical prediction score for transient versus persistent childhood immune thrombocytopenia. Schmidt DE; Wendtland Edslev P; Heitink-Pollé KMJ; Mertens B; Bruin MCA; Kapur R; Vidarsson G; van der Schoot CE; Porcelijn L; van der Bom JG; Rosthøj S; de Haas M J Thromb Haemost; 2021 Jan; 19(1):121-130. PubMed ID: 33058474 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Anti-D Immunoglobulins versus Intravenous Immunoglobulins for Immune Thrombocytopenia in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials. Lioger B; Maillot F; Ternant D; Passot C; Paintaud G; Bejan-Angoulvant T J Pediatr; 2019 Jan; 204():225-233.e8. PubMed ID: 30314658 [TBL] [Abstract][Full Text] [Related]
8. Identification of predictive factors for response to intravenous immunoglobulin treatment in children with immune thrombocytopenia. Morimoto Y; Yoshida N; Kawashima N; Matsumoto K; Kato K Int J Hematol; 2014; 99(5):597-602. PubMed ID: 24573984 [TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin G and anti-D as therapeutic interventions in immune thrombocytopenic purpura. Blanchette V; Carcao M Transfus Sci; 1998 Sep; 19(3):279-88. PubMed ID: 10351140 [TBL] [Abstract][Full Text] [Related]
14. Biological stratification of clinical disease courses in childhood immune thrombocytopenia. Schmidt DE; Heitink-Pollé KMJ; Mertens B; Porcelijn L; Kapur R; van der Schoot CE; Vidarsson G; van der Bom JG; Bruin MCA; de Haas M J Thromb Haemost; 2021 Apr; 19(4):1071-1081. PubMed ID: 33386662 [TBL] [Abstract][Full Text] [Related]
15. Possible lower rate of chronic ITP after IVIG for acute childhood ITP an analysis from registry I of the Intercontinental Cooperative ITP Study Group (ICIS). Tamminga R; Berchtold W; Bruin M; Buchanan GR; Kühne T Br J Haematol; 2009 Jul; 146(2):180-4. PubMed ID: 19466971 [TBL] [Abstract][Full Text] [Related]